Tumor genomic profiling showed signature alterations consistent with sporadic urothelial carcinoma (Subjects 14), sporadic angiosarcoma, (Subjects 15), and sporadic cholangiocarcinoma (Subjects 16), the collective sum of evidence suggests these germline TP53 variants are not involved in LFS tumorigenicity, and they are unlikely to be actionable (Table 2). This evidence concerns the gene TP53 and angiosarcoma.